GlassScriptPhysician profile
Caleb R Overpeck
NPI 1740576529
$6,232.88
in general payments reported to CMS, 2019-2025
35 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,678 · 2020: $1,853 · 2021: $2,190 · 2022: $80.61 · 2023: $118 · 2024: $140 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.59 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,036.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $870.08 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $626.81 | 2019-2021 | |
| Lilly USA, LLC | $550.22 | 2019-2021 | |
| Pfizer INC. | $398.02 | 2019-2025 | |
| Novo Nordisk INC | $357.39 | 2019-2025 | Wegovy |
| Allergan, INC. | $327.33 | 2019-2020 | |
| Abbvie INC. | $307.23 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.25 | 2019-2022 | |
| Amarin Pharma, INC. | $208.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $164.87 | 2019-2025 | Proquad, Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $137.02 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $90.48 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $80.19 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $70.32 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $60.01 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $51.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $48.24 | 2019-2020 | |
| Daiichi Sankyo INC. | $47.42 | 2020-2021 | |
| Astellas Pharma US INC | $46.59 | 2019-2021 | |
| Horizon Therapeutics Plc | $37.98 | 2019 | |
| Exact Sciences Corporation | $33.84 | 2024-2025 | Cologuard Collection Kit |
| Nevro Corp. | $27.67 | 2019 | |
| Edwards Lifesciences Corporation | $27.49 | 2025 | Sapien 3 Ultra Resilia |
| Ironwood Pharmaceuticals, INC | $22.94 | 2021 | |
| Boston Scientific Corporation | $21.35 | 2025 | Watchman Flx |
| Mylan Specialty L.P. | $14.53 | 2019 | |
| Circassia INC. | $14.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.91 | 2020 | |
| Ethicon US, LLC | $12.49 | 2021 | |
| Currax Pharmaceuticals LLC | $12.36 | 2020 | |
| Ibsa Pharma INC. | $12.10 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.47 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Overpeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.